Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy

Br J Ophthalmol. 2017 Apr;101(4):433-437. doi: 10.1136/bjophthalmol-2016-308921. Epub 2016 Jul 7.

Abstract

Background/aims: To investigate the changes in the intrachoroidal structures after half-dose verteporfin photodynamic therapy (PDT) for central serous chorioretinopathy (CSC).

Methods: Swept-source optical coherence tomography cross-sectional images of 22 eyes of 22 patients with CSC were retrospectively analysed by a manual delineation technique and binarisation method.

Results: In the 22 eyes, the mean subfoveal choroidal thickness decreased from 412.9±112.9 μm at baseline to 340.0±111.0 μm at 3 months (p<0.0001). The mean thickness of the large choroidal vessel layer decreased from 368.7±112.7 μm at baseline to 292.2±118.0 μm at 3 months (p<0.0001), but the mean choriocapillaris-medium choroidal vessel layer thickness did not change from 44.2±29.2 μm at baseline to 47.8±25.7 μm at 3 months (p=0.85). Analyses of the binarised choroidal images showed that a 3 mm subfoveal choroidal area decreased from 1.141±0.290 mm2 at baseline to 0.962±0.320 mm2 at 3 months after PDT (p=0.0001). The mean luminal areas decreased from 0.826±0.246 mm2 at baseline to 0.665±0.234 mm2 at 3 months (p=0.0001), however, the mean stromal areas did not change from 0.315±0.066 mm2 at baseline to 0.297±0.095 mm2 at 3 months (p=0.60).

Conclusions: Half-dose PDT reduces subfoveal choroidal thickness and alters the intrachoroidal structures in eyes with CSC.

Keywords: Choroid; Imaging; Macula; Treatment Lasers; Treatment Medical.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Central Serous Chorioretinopathy / diagnostic imaging
  • Central Serous Chorioretinopathy / drug therapy*
  • Central Serous Chorioretinopathy / physiopathology
  • Choroid / diagnostic imaging
  • Choroid / drug effects
  • Choroid / pathology*
  • Female
  • Fluorescein Angiography*
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use*
  • Porphyrins / therapeutic use*
  • Retrospective Studies
  • Tomography, Optical Coherence*
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin